Frontline treatment of IDH1-mutated myelodysplastic syndrome with ivosidenib: clinical cases and therapeutic insights.
作者信息
Antonios Bana, Dutton Nina, Fazal Salman
机构信息
Allegheny Health Network Cancer Institute, 314 E North Avenue, Pittsburgh, PA 15212-3002, USA.
Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.
出版信息
Ther Adv Hematol. 2025 Sep 7;16:20406207251372766. doi: 10.1177/20406207251372766. eCollection 2025.
Abstract
摘要
相似文献
1
Frontline treatment of IDH1-mutated myelodysplastic syndrome with ivosidenib: clinical cases and therapeutic insights.ivosidenib一线治疗异柠檬酸脱氢酶1（IDH1）突变的骨髓增生异常综合征：临床病例与治疗见解
Ther Adv Hematol. 2025 Sep 7;16:20406207251372766. doi: 10.1177/20406207251372766. eCollection 2025.
2
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.依维替尼联合纳武利尤单抗治疗携带异柠檬酸脱氢酶1（IDH1）突变的晚期实体瘤的临床及转化研究
medRxiv. 2025 Jul 21:2025.07.19.25331848. doi: 10.1101/2025.07.19.25331848.
3
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.美国食品药品监督管理局批准摘要：艾伏尼布用于治疗携带异柠檬酸脱氢酶-1（IDH1）突变的复发/难治性骨髓增生异常综合征成年患者。
Clin Cancer Res. 2025 Jul 1. doi: 10.1158/1078-0432.CCR-25-1005.
4
Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study.艾伏尼布治疗异柠檬酸脱氢酶1（IDH1）突变型肝内胆管癌：一项多中心真实世界研究的见解
Liver Int. 2025 Sep;45(9):e70295. doi: 10.1111/liv.70295.
5
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.阿扎胞苷联合艾伏尼布对比安慰剂治疗新诊断的异柠檬酸脱氢酶1（IDH1）突变型急性髓系白血病（AML）的AGILE研究的长期结果。
Blood Adv. 2025 Jul 24. doi: 10.1182/bloodadvances.2025016399.
6
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.ivosidenib 联合 venetoclax ± 阿扎胞苷治疗 IDH1 突变型髓系恶性肿瘤的 Ib/II 期研究。
Blood Cancer Discov. 2023 Jul 5;4(4):276-293. doi: 10.1158/2643-3230.BCD-22-0205.
7
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.对于不符合强化化疗条件的异柠檬酸脱氢酶（IDH）突变型急性髓系白血病（AML）患者，采用去甲基化药物、维奈克拉和异柠檬酸脱氢酶抑制剂的一线三联方案的疗效。
J Clin Oncol. 2025 Aug 20;43(24):2692-2699. doi: 10.1200/JCO-25-00640. Epub 2025 Jun 13.
8
Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia.ivosidenib与其他疗法在新诊断急性髓系白血病患者中的间接治疗比较。
Future Oncol. 2025 Jul;21(17):2225-2235. doi: 10.1080/14796694.2025.2515778. Epub 2025 Jun 10.
9
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS.异柠檬酸脱氢酶抑制剂在成年 AML 和 MDS 患者治疗中的研究进展。
Expert Rev Hematol. 2024 Nov;17(11):755-767. doi: 10.1080/17474086.2024.2422554. Epub 2024 Nov 7.
10
Novel small-molecule therapies for myelodysplastic syndromes with IPSS-R ⩾3.5 in patients aged 60 or older: current landscape and challenges.针对国际预后评分系统修订版（IPSS-R）≥3.5的60岁及以上骨髓增生异常综合征患者的新型小分子疗法：现状与挑战
Ther Adv Hematol. 2025 Sep 3;16:20406207251371298. doi: 10.1177/20406207251371298. eCollection 2025.
本文引用的文献
1
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.ivosidenib 治疗 IDH1 突变复发/难治性骨髓增生异常综合征患者的最终 1 期亚组研究结果。
Blood Adv. 2024 Aug 13;8(15):4209-4220. doi: 10.1182/bloodadvances.2023012302.
2
How we treat lower-risk myelodysplastic syndromes.如何治疗低危骨髓增生异常综合征。
Blood. 2013 May 23;121(21):4280-6. doi: 10.1182/blood-2013-02-453068. Epub 2013 Apr 10.
3
Hematopoietic growth factors in myelodysplastic syndromes.骨髓增生异常综合征中的造血生长因子。
Semin Oncol. 2011 Oct;38(5):635-47. doi: 10.1053/j.seminoncol.2011.04.014.
Zotero 插件